438 related articles for article (PubMed ID: 12173277)
1. Results from a patient survey to assess gastrointestinal burden of non-steroidal anti-inflammatory drug therapy contrasted with a review of data from EVA to determine satisfaction with rofecoxib.
Steinfeld S; Bjørke PA
Rheumatology (Oxford); 2002 Apr; 41 Supp 1():23-7; discussion 35-42. PubMed ID: 12173277
[TBL] [Abstract][Full Text] [Related]
2. Patient and physician satisfaction with rofecoxib in osteoarthritis: results of the EVA (experience with VIOXX in arthritis) survey.
Steinfeld S; Poriau S
Curr Med Res Opin; 2001; 17(2):81-7. PubMed ID: 11759186
[TBL] [Abstract][Full Text] [Related]
3. Experience of rofecoxib in patients with osteoarthritis previously treated with traditional non-steroidal anti-inflammatory drugs in Spain: results of phase 2 of the VICOXX study.
Arboleya LR; de la Figuera E; Soledad García M; Aragón B;
Curr Med Res Opin; 2003; 19(4):288-97. PubMed ID: 12841921
[TBL] [Abstract][Full Text] [Related]
4. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
Maetzel A; Krahn M; Naglie G
Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
[TBL] [Abstract][Full Text] [Related]
5. The trade-off between cardiovascular and gastrointestinal effects of rofecoxib.
Florentinus SR; Heerdink ER; de Boer A; van Dijk L; Leufkens HG
Pharmacoepidemiol Drug Saf; 2005 Jul; 14(7):437-41. PubMed ID: 15937867
[TBL] [Abstract][Full Text] [Related]
6. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
[TBL] [Abstract][Full Text] [Related]
7. Persistency of use of COX-2-specific inhibitors and non-specific non-steroidal anti-inflammatory drugs (NSAIDs) in Quebec.
Moride Y; Ducruet T; Rochon S; Lavoie F
Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii17-22. PubMed ID: 14585914
[TBL] [Abstract][Full Text] [Related]
8. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
Hochberg MC
Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
[TBL] [Abstract][Full Text] [Related]
9. Clinical experience with cyclooxygenase-2 inhibitors.
Lanas A
Rheumatology (Oxford); 2002 Apr; 41 Supp 1():16-22; discussion 35-42. PubMed ID: 12173276
[TBL] [Abstract][Full Text] [Related]
10. Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs.
Zhao SZ; Wentworth C; Burke TA; Makuch RW
Pharmacoepidemiol Drug Saf; 2004 May; 13(5):277-87. PubMed ID: 15133778
[TBL] [Abstract][Full Text] [Related]
11. Underutilization of preventive strategies in patients receiving NSAIDs.
Sturkenboom MC; Burke TA; Dieleman JP; Tangelder MJ; Lee F; Goldstein JL
Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii23-31. PubMed ID: 14585915
[TBL] [Abstract][Full Text] [Related]
12. Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S401-13. PubMed ID: 12416790
[TBL] [Abstract][Full Text] [Related]
13. Over-the-counter nonsteroidal anti-inflammatory drugs and risk of gastrointestinal symptoms.
Thomas J; Straus WL; Bloom BS
Am J Gastroenterol; 2002 Sep; 97(9):2215-9. PubMed ID: 12358235
[TBL] [Abstract][Full Text] [Related]
14. Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs.
Watson DJ; Harper SE; Zhao PL; Bolognese JA; Simon TJ
MedGenMed; 2001 Nov; 3(4):6. PubMed ID: 11965201
[TBL] [Abstract][Full Text] [Related]
15. Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis.
Rabeneck L; Goldstein JL; Vu A; Mayne TJ; Rublee DA
Am J Gastroenterol; 2005 May; 100(5):1043-50. PubMed ID: 15842577
[TBL] [Abstract][Full Text] [Related]
16. [The lack of awareness of the Israeli population regarding gastrointestinal complications from non-steroidal anti-inflammatory drugs].
Zandman-Goddard G; Langevitz P
Harefuah; 2001 Jun; 140(6):476-8, 567, 566. PubMed ID: 11420844
[TBL] [Abstract][Full Text] [Related]
17. Nonsteroidal anti-inflammatory drugs in the elderly.
Buffum M; Buffum JC
Pain Manag Nurs; 2000 Jun; 1(2):40-50. PubMed ID: 11706458
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
[TBL] [Abstract][Full Text] [Related]
19. Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations.
Lazzaroni M; Bianchi Porro G
Aliment Pharmacol Ther; 2004 Jul; 20 Suppl 2():48-58. PubMed ID: 15335413
[TBL] [Abstract][Full Text] [Related]
20. Pharmacoutilization and costs of osteoarthritis: changes induced by the introduction of a cyclooxygenase-2 inhibitor into clinical practice.
Russo P; Capone A; Attanasio E; Baio G; Di Martino M; Degli Esposti L; Marchetta F; Buda S; Degli Esposti E; Caprino L
Rheumatology (Oxford); 2003 Jul; 42(7):879-87. PubMed ID: 12730549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
